臨床泌尿器科73巻6号

2019年05月発行

特集 これだけは押さえておきたい! 泌尿器腫瘍に対する抗がん剤の基本

〈抗がん剤治療〉

進行性胚細胞腫瘍に対するBEP療法においてRDIを高く維持することの重要性

著者： 河野勤¹

所属機関： ¹佐々木研究所附属杏雲堂病院腫瘍内科

ページ範囲：P.366 - P.373

文献概要

▶ポイント

・BEP療法は，単剤で胚細胞腫瘍に有効な3種の薬剤を組み合わせ，なおかつDLFを腎毒性，骨髄毒性，肺毒性に分散しえた点で理想的な併用化学療法である．

・RDIは，PDIに対するADIの割合である．

・BEP療法ではRDIを高く維持することが重要である．

参考文献

1） Williams SD, Birch R, Einhorn LH, et al : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 : 1435-1440, 1987

2） International Germ Cell Consensus Classification : a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15 : 594-603, 1997

3） Culine S, Kerbrat P, Kramar A, et al : Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers （GETUG T93BP）. Ann Oncol 18 : 917-924, 2007

4） Hinton S, Catalano PJ, Einhorn LH, et al : Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors : final analysis of an intergroup trial. Cancer 97 : 1869-1875, 2003

5） Higby DJ, Wallace HJ Jr, Albert DJ, et al : Diaminodichloroplatinum : a phase I study showing responses in testicular and other tumors. Cancer 33 : 1219-1215, 1974

6） CISPLATIN clinical experience overview. Bristol

7） Hanna N and Einhorn LH : Testicular Cancer : A Reflection on 50 Years of Discovery. J Clin Oncol 32 : 3085-3092, 2014

8） Loehrer PJ Sr, Johnson D, Elson P, et al : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors : an Eastern Cooperative Oncology Group trial. J Clin Oncol 13 : 470-476, 1995

9） de Wit R, Stoter G, Kaye SB, et al : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 : 1837-1843, 1997

10） Samson MK, Rivkin SE, Jones SE, et al : Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53 : 1029-1035, 1984

11） Nichols CR, Williams SD, Loehrer PJ, et al : Randomized study of cisplatin dose intensity in poor-risk germ cell tumors : a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9 : 1163-1172, 1991

12） Toner GC, Stockler MR, Boyer MJ, et al : Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours : a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357 : 739-745, 2001

13） Collette L, Sylvester RJ, Stenning SP, et al : Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91 : 839-846, 1999

14） Fosså SD, Kaye SB, Mead GM, et al : Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. Journal of Clinical Oncology 16 : 716-724, 1998

15） Culine S, Kramar A, Théodore C, et al : Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors : Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26 : 421-427, 2008

16） Aapro MS, Bohlius J, Cameron DA, et al : 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47 : 8-32, 2011

17） Andreatos N, Flokas ME, Apostolopoulou A, et al : The Dose-Dependent Efficacy of cefepime in the Empiric Management of Febrile Neutropenia : A Systematic Review and Meta-Analysis. Open Forum Infect Dis 4 : ofx113, 2017

18） Albers P, Albrecht W, Algaba F, et al : Guidelines on Testicular Cancer : 2015 Update. Eur Urol 68 : 1054-1068, 2015

19） Motzer RJ, Geller NL, and Bosl GJ : The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer 66 : 857-861, 1990

20） Feldman DR : State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book : 319-323, 2018